Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab - Bristol Myers Squibb

X
Drug Profile

Ipilimumab - Bristol Myers Squibb

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; BioGene Pharmaceutical; Bristol-Myers Squibb; Canadian Cancer Trials Group; Cancer Research Institute; Concentra Biosciences; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Icahn School of Medicine at Mount Sinai; Intergroupe Francophone de Cancerologie Thoracique; Jazz Pharmaceuticals Inc; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Medarex; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National University Hospital (Singapore); Netherlands Cancer Institute; Northwestern University; Novartis; Olivia Newton-John Cancer Research Institute; OncoTherapy Science; Ono Pharmaceutical; Oslo University Hospital; Parker Institute for Cancer Immunotherapy; Providence Health & Services; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University College London; University of California at San Francisco; University of Leeds; University of Pittsburgh; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
  • Registered Colorectal cancer
  • Preregistration Oesophageal cancer
  • Phase III Gastric cancer; Glioblastoma; Prostate cancer; Small cell lung cancer; Urogenital cancer
  • Phase II Adrenocortical carcinoma; Breast cancer; Cancer; CNS cancer; Gastrointestinal cancer; Genitourinary disorders; Gynaecological cancer; Hodgkin's disease; Liver metastases; Meningeal carcinomatosis; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Penile cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Phase I/II Adrenal cancer; Diffuse large B cell lymphoma; Lung cancer
  • Phase I Neurofibrosarcoma
  • No development reported Glioma; HIV infections; Lymphoma

Most Recent Events

  • 20 Mar 2024 Efficacy and adverse event data from the phase III CheckMate 9DW trial in Liver cancer released by Bristol-Myers Squibb
  • 01 Feb 2024 Bristol-Myers Squibb completes a phase-III CheckMate 914 clinical trials in Renal cell carcinoma (Combination therapy, Adjuvant therapy) US, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Singapore, Spain, Switzerland, Turkey, United Kingdom (IV) (EudraCT2016-004502-34) (NCT03138512 (700284486)
  • 22 Jan 2024 Efficacy and adverse events data from the phase CheckMate-214 trial in Renal cell carcinoma released by Bristol-Myers Squibb
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top